Rocket Pharmaceuticals Inc

NASDAQ:RCKTUnited States

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

Contact Information

Headquarters

350 5th Ave Ste 7530NEW YORK, NY, United States 10118-7501

Phone

646-440-9100

Fax

781-676-2155

Executives

Chairman of the Board

Roderick Wong

President, Chief Operating Officer, Head of Research and Development

Kinnari Patel

Chief Executive Officer, Director

Gaurav Shah

Chief Financial Officer, Principal Financial Officer

Aaron Ondrey

Executive Vice President, Chief Technical Officer

Mayo Pujols